QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
QuidelOrtho CorporationNASDAQ: QDEL
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $619.8M fell 10.5% year over year, behind the -3.9% change in trailing-twelve-month revenue. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $2.52B (-7.7%) for the fiscal year ending Dec 2026, a slowdown from the -1.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $619.8M-14.3% QoQ
- Last fiscal yearDec 2025
- $2.73B-1.9% YoY
- LTMMar 2026
- $2.66B-3.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.5% | +1.3% | +11.8 pp |
| 1 year | -1.9% | -7.7% | -5.8 pp |
| 3-year CAGR | -5.8% | -1.8% | +4.0 pp |
| 5-year CAGR | +0.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 2.73B USD
- Year-over-year change
- -1.9%
- 4-year CAGR
- +12.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 2.73B | -1.9% |
| FY2024 | 2024-12-29 | 2.78B | -7.2% |
| FY2023 | 2023-12-31 | 3B | -8.2% |
| FY2022 | 2023-01-01 | 3.27B | +92.3% |
| FY2021 | 2021-12-31 | 1.7B | — |
Revenue vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's LTM Mar 2026 revenue of $2.66B is the 4th highest of the 9 companies compared; the peer median is $1.59B.
- Its year-over-year change of -3.9% is the 6th highest of 9, against a peer median of +2.7%.
- Over three fiscal years its annual growth of -5.8% compares with a peer median of -8.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $47.35B | +8.3% | -0.3% | |
| LTM Sep 2026 | $11.84B | +9.1% | +3.7% | |
| LTM Jul 2026 | $2.91B | +4.1% | -4.8% | |
| LTM Mar 2026 | $2.66B | -3.9% | -5.8% | |
| LTM Jun 2026 | $2.59B | +1.4% | -2.7% | |
| LTM Mar 2026 | $581.12M | -15.7% | -15.5% | |
| LTM Mar 2026 | $113.02M | -30.1% | -33.3% | |
| LTM Dec 2025 | $43.86M | -28.7% | -11.2% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $9.76M | +19.2% | -25.4% |
| Peer median (excluding QDEL) | $1.59B | +2.7% | -8.0% | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.7B | 3.27B | 3B | 2.78B | 2.73B |
| Cost of Revenue | 420.3M | 1.33B | 1.5B | 1.5B | 1.46B |
| Gross Profit | 1.28B | 1.94B | 1.5B | 1.29B | 1.27B |
| Gross Margin | 75.3% | 59.3% | 49.9% | 46.2% | 46.7% |
| Research & Development | 95.7M | 187.9M | 246.8M | 218.7M | 186.2M |
| Selling, General & Admin | 239.6M | 621M | 763.2M | 766.8M | 746.3M |
| Operating Expenses | 372.3M | 1.09B | 1.36B | 3.25B | 2.19B |
| Depreciation & Amortization | 52.7M | 283.6M | 457.2M | 453.4M | 442M |
| EBITDA | 953.3M | 1.09B | 607M | (1.49B) | (488.1M) |
| EBITDA Margin | 56.1% | 33.5% | 20.2% | -53.5% | -17.9% |
| Operating Income | 906M | 843.7M | 139.1M | (1.96B) | (919.2M) |
| Operating Margin | 53.3% | 25.8% | 4.6% | -70.5% | -33.7% |
| Interest Income | 300K | 1.3M | 2.2M | 0 | 0 |
| Interest Expense | 700K | 74.5M | 178.9M | 188.3M | 177.6M |
| Other Income / Expenses | (5.7M) | (107.8M) | (168.2M) | (170.6M) | (188.5M) |
| Income Before Tax | 900.3M | 735.9M | (29.1M) | (2.13B) | (1.11B) |
| Pre-Tax Margin | 53.0% | 22.5% | -1.0% | -76.6% | -40.6% |
| Income Tax Expense | 196.1M | 187.2M | (19M) | (79.5M) | 24.1M |
| Net Income | 704.2M | 548.7M | (10.1M) | (2.05B) | (1.13B) |
| Net Margin | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% |
| EPS (Basic) | 16.74 | 9.66 | (0.15) | (30.54) | (16.69) |
| EPS (Diluted) | 16.43 | 9.56 | (0.15) | (30.54) | (16.69) |
| Weighted Avg Shares | 42.08M | 56.8M | 66.8M | 67.2M | 67.8M |
| Weighted Avg Shares (Diluted) | 42.87M | 57.4M | 66.8M | 67.2M | 67.8M |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.